Hengrui Pharma (600276) Announces Share Repurchase Update

Bulletin Express

11/04

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital following a repurchase of 210,000 A shares on 04 November 2025 for the A Share Employee Stock Ownership Schemes. The repurchase occurred on the Shanghai Stock Exchange at prices ranging between RMB 61.6 and RMB 62.3 per share, with a total payment of approximately RMB 13,022,079.8.

After the transaction, the number of issued shares (excluding treasury shares) decreased to 6,362,422,164 from 6,362,632,164, while treasury shares increased to 16,580,110. The total number of shares remained at 6,379,002,274. The filing confirms that all related procedures have been carried out in compliance with applicable listing rules and regulatory requirements.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1164474906"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164474906\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164474906?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164474906","market":"hk","top_or_hot":-1,"title":"Hengrui Pharma (600276) Announces Share Repurchase Update","media":"Bulletin Express","content":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital following a repurchase of 210,000 A shares on 04 November 2025 for the A Share Employee Stock Ownership Schemes. The repurchase occurred on the Shanghai Stock Exchange at prices ranging between RMB 61.6 and RMB 62.3 per share, with a total payment of approximately RMB 13,022,079.8.</p>\n<p>After the transaction, the number of issued shares (excluding treasury shares) decreased to 6,362,422,164 from 6,362,632,164, while treasury shares increased to 16,580,110. The total number of shares remained at 6,379,002,274. The filing confirms that all related procedures have been carried out in compliance with applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharma (600276) Announces Share Repurchase Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharma (600276) Announces Share Repurchase Update\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-11-04 16:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital following a repurchase of 210,000 A shares on 04 November 2025 for the A Share Employee Stock Ownership Schemes. The repurchase occurred on the Shanghai Stock Exchange at prices ranging between RMB 61.6 and RMB 62.3 per share, with a total payment of approximately RMB 13,022,079.8.</p>\n<p>After the transaction, the number of issued shares (excluding treasury shares) decreased to 6,362,422,164 from 6,362,632,164, while treasury shares increased to 16,580,110. The total number of shares remained at 6,379,002,274. The filing confirms that all related procedures have been carried out in compliance with applicable listing rules and regulatory requirements.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恆瑞醫藥","start_time":0,"source_url":"","article_id":"1164474906","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164474906","pubTimestamp":1762245901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"恒瑞医药(600276)公布回购股份更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital following a repurchase of 210,000 A shares on 04 November 2025 for the A Share Employee Stock Ownership Schemes. The repurchase occurred on the Shanghai Stock Exchange at prices ranging between RMB 61.6 and RMB 62.3 per share, with a total payment of approximately RMB 13,022,079.8.\nAfter the transaction, the number of issued shares (excluding treasury shares) decreased to 6,362,422,164 from 6,362,632,164, while treasury shares increased to 16,580,110. The total number of shares remained at 6,379,002,274. The filing confirms that all related procedures have been carried out in compliance with applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}